Status:
RECRUITING
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Collaborating Sponsors:
Centre Hospitalier Saint Vincent
Centre Henri Becquerel
Conditions:
Hyperviscosity Syndrome
Waldenstrom Macroglobulinemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Walsdenström Macroglobulinemia (WM) is defined by a bone marrow lymphoplasmacytic infiltration and the presence of a monoclonal immunoglobulin M (IgM) in blood. Clinical manifestations of the hypervis...
Eligibility Criteria
Inclusion
- Patient with WM
- Patients that may require a first-line or subsequent-line therapy
- patients who will require treatment initiation
- patients with serum monoclonal component concentration greater than 15 g/L and who will underwent hyperviscosity assessment, even if hyperviscosity is not found and in the absence of other treatment criteria, no treatment is finally initiated.
- Patients agreeing to give informed consent.
Exclusion
- Patients with another chronic B-cell malignancy
- patients with lymphoplasmacytic proliferations
- patients with marginal zone lymphoma.
- patients with WM and histologic transformation
- Absence of informed consent.
Key Trial Info
Start Date :
May 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04898647
Start Date
May 14 2021
End Date
August 1 2026
Last Update
May 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France, 80480